molybdenum has been researched along with Hyperuricemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, G; Gu, T; Hou, R; Leng, M; Luo, M; Xue, T; Zhang, N | 1 |
| Chen, C; Lü, JM; Yao, Q | 1 |
| Bell, CE; Hille, R; Pauff, JM; Zhang, J | 1 |
1 review(s) available for molybdenum and Hyperuricemia
| Article | Year |
|---|---|
A systematic review and meta-analysis of the hyperuricemia risk from certain metals.
Topics: Arsenic; Cadmium; Calcium; Cross-Sectional Studies; Humans; Hyperuricemia; Molybdenum; United States | 2022 |
2 other study(ies) available for molybdenum and Hyperuricemia
| Article | Year |
|---|---|
3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Topics: Administration, Oral; Allopurinol; Animals; Antioxidants; Benzaldehydes; Catechols; Cell-Free System; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Gout Suppressants; Hyperuricemia; Inhibitory Concentration 50; Mice; Mice, Inbred C57BL; Molybdenum; Reactive Oxygen Species; Structure-Activity Relationship; Uric Acid; Xanthine Oxidase | 2013 |
Substrate orientation in xanthine oxidase: crystal structure of enzyme in reaction with 2-hydroxy-6-methylpurine.
Topics: Animals; Binding Sites; Catalysis; Cattle; Crystallography, X-Ray; Humans; Hyperuricemia; Molybdenum; NAD; Protein Binding; Protein Structure, Tertiary; Purines; Xanthine Oxidase | 2008 |